Best in Biotech 14 Nov 2024
8 biotech companies advancing new treatments for breast cancer in 2024
…options. BNT323 is an antibody-drug conjugate (ADC) targeting HER2-expressing cancers, including HER2-low metastatic breast cancer. ADCs combine the specificity of monoclonal antibodies with the potency of chemotherapy. In the case…